常规分割与大分割乳房切除术后放疗的长期结局与晚期毒性对比
中位随访71.8个月,两组5年局部区域无复发生存、无病生存和总生存均无显著差异;在937例可评估晚期毒性的患者中,大分割组≥2级晚期皮肤和皮下毒性发生率显著更高,但≥2级晚期肺毒性和1级臂丛神经病发生率显著更低,心脏毒性和淋巴水肿两组相似。
要点
- 大分割与常规分割放疗的5年LRRFS、DFS、OS均无显著差异。
- 大分割组≥2级晚期皮肤(4% vs 1%)和皮下(7% vs 2%)毒性显著更高。
- 大分割组≥2级晚期肺毒性(9% vs 16%)和1级臂丛神经病(2% vs 8%)显著更低。
核心结论
- 大分割乳房切除术后放疗可行,长期疗效与常规分割放疗相当。
- 大分割组≥2级晚期皮肤和皮下毒性更高,但肺毒性和臂丛神经毒性更低。
研究设计与样本
- 中位随访71.8个月(范围41.5-115.9个月);晚期毒性评估队列937例,中位随访106.3个月(范围76-134个月)。
主要发现
- 5年局部区域无复发生存率大分割组 vs 常规分割组为96% vs 94%(p=0.373)。
- 5年无病生存率为70% vs 72%(p=0.849),总生存率为73% vs 74%(p=0.463)。
- ≥2级晚期皮肤毒性为4% vs 1%,皮下毒性为7% vs 2%,大分割组更高。
- ≥2级晚期RTOG/EORTC肺毒性为9% vs 16%,1级臂丛神经病为2% vs 8%,大分割组更低。
- 心脏毒性和淋巴水肿两组相似;大分割组接受额外放疗推量的患者显著更多。
关键数值与推荐
- 大分割放疗方案:2.65 Gy/次,总剂量42.4-53 Gy。
- 常规分割放疗方案:2 Gy/次,总剂量50-60 Gy。
- 晚期毒性评估采用RTOG/EORTC标准,评估≥2级皮肤、皮下、肺毒性及1级臂丛神经病等。
临床怎么用
- 大分割乳房切除术后放疗可作为常规分割的可行选择,长期疗效相当。
- 采用大分割方案时需关注晚期皮肤和皮下毒性风险,尤其是接受额外推量的患者。
- 大分割可能降低肺和臂丛神经毒性,但需结合患者个体情况权衡。
局限性
- 回顾性队列设计,可能存在选择偏倚。
- 大分割组接受额外放疗推量的患者显著更多,可能影响毒性比较。
- 晚期毒性评估仅纳入937例 eligible 患者,非全部队列。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We evaluated the long-term outcomes and late toxicity of conventional fractionated (CF) and hypofractionated (HF) postmastectomy radiotherapy (PMRT) in terms of locoregional recurrence-free survival (LRRFS), disease-free survival (DFS), overall survival (OS), and late toxicity. METHODS: A cohort of 1640 of breast cancer patients receiving PMRT between January 2004 and December 2014 were enrolled. Nine hundred eighty patients were treated with HF-PMRT: 2.65 Gy/fraction to a total of 42.4-53 Gy and 660 patients were treated with CF-PMRT: 2 Gy/fraction to a total of 50-60 Gy. RESULTS: The median follow-up time was 71.8 months (range 41.5-115.9 months). No significant difference was found in the rates of 5-year LRRFS, DFS, and OS of HF-PMRT vs CF-PMRT; 96% vs. 94% (p = 0.373), 70% vs. 72% (p = 0.849), and 73% vs. 74% (p = 0.463), respectively. We identified a cohort of 937 eligible breast cancer patients who could receive late toxicities assessment. With a median follow-up time of this patient cohort of 106.3 months (range 76-134 months), there was a significant higher incidence of grade 2 or more late skin (4% vs 1%) and subcutaneous (7% vs 2%) toxicity in patients treated with HF-PMRT vs CF-PMRT. Patients who received additional radiation boost were significantly higher in the HF-PMRT group. Grade 2 or more late RTOG/EORTC lung toxicity was significant lesser in HF-PMRT vs CF-PMRT (9% vs 16%). Grade 1 brachial plexopathy was also significant lesser in HF-PMRT vs CF-PMRT (2% vs 8%). Heart toxicity and lymphedema were similar in both groups. CONCLUSIONS: HF-PMRT is feasible to deliver with comparable long-term efficacy to CF-PMRT. HF-PMRT had higher grade 2 or more skin and subcutaneous toxicity but less lung and brachial plexus toxicity.
引用
- Chitapanarux I, Klunklin P, Pinitpatcharalert A, et al. Conventional versus hypofractionated postmastectomy radiotherapy: a report on long-term outcomes and late toxicity. Radiat Oncol. 2019. PMID: 31610801. doi:10.1186/s13014-019-1378-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。